Nanoparticle therapy for allergic and inflammatory disease

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 9, Issue 1, 2010, Pages 54-70

  Fraser, Christopher C ^a  

^a Selecta Biosciences   (United States)

Author keywords

Allergy; Anergy; Antigen; Epitope; Immunotherapy; Inflammation; Nanoparticle

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTIASTHMATIC AGENT; BEE VENOM; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; CAT ALLERGEN; CHITOSAN; CORTICOSTEROID; CYCLODEXTRIN; CYCLOSPORIN A; FOOD ALLERGEN; GAMMA INTERFERON PLASMID; GANTREZ COPOLYMER; HEPARIN; HOUSE DUST ALLERGEN; LIPOSOME; METHYLPREDNISOLONE; MILK ALLERGEN; OLIVE OIL; P SELECTIN ANTAGONIST; POLLEN ANTIGEN; POLYGLACTIN; PREDNISOLONE; RAPAMYCIN; ROLIPRAM; TACROLIMUS; TAMOXIFEN; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ASTHMA; ALLERGY; ARTHRITIS; ASTHMA; ATHEROMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; AUTOINFLAMMATORY DISEASE; CLINICAL EFFECTIVENESS; DRUG DELIVERY SYSTEM; ENTERITIS; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LOLIUM; NONHUMAN; POLLEN ALLERGY; REVIEW; RHEUMATOID ARTHRITIS; SPINAL CORD INJURY; UNSPECIFIED SIDE EFFECT; UVEORETINITIS;

EID: 77950835741     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152310790711683     Document Type: Review

References (313)

1. Goriely, S.; Cavoy, R.; Goldman, M. Interleukin-12 family members and type 1 interferons in Th17-mediated inflammatory disorders. Allergy, 2009, 64, 702-709.
2. Akdis, M; Blaser, K; Akdis, C. A. T regulatory cells in allergy. Chem. Immunol. Allergy, 2006, 91, 159-173.
3. Oboki, K.; Ohno, T.; Saito, H.; Nakae, S. Th17 and allergy. Allergol. Int., 2008, 57, 121-134.
4. Wang, Y. H.; Liu, Y. J. The IL-17 cytokine family and their role in allergic inflammation. Curr. Opin. Immunol., 2008, 20, 697-702.
5. Schmidt-Weber, C.B. Th17 and treg cells innovate the TH1/TH2 concept and allergy research. Chem. Immunol. Allergy, 2008, 94, 1-7.
6. Broide, D. H. Immunomodulation of allergic disease. Annu. Rev. Med., 2009, 60, 279-291.
7. Akdis, M.; Akdis, C. A. Therapeutic manipulation of immune tolerance in allergic disease. Nat. Rev. Drug Discov., 2009, 8, 645-660.
8. Bonura, A.; Colombo, P. Genetic engineering of allergens for immunotherapy. Inflamm. Allergy Drug Targets, 2009, 8, 104-109.
9. Rolland, J. M.; Gardner, L. M.; O'Hehir, R. E. Allergen-related approaches to immunotherapy. Pharmacol. Ther., 2009, 121, 273-284.
10. Chua, K.Y.; Kuo, I. C.; Huang, C. H. DNA vaccines for the prevention and treatment of allergy. Curr. Opin. Allergy Clin. Immunol., 2009, 9, 50-54.
11. Hamid, Q.; Tulic, M. Immunobiology of asthma. Annu. Rev. Physiol., 2009, 71, 489-507.
12. Long, A. A. Immunomodulators in the treatment of asthma. Allergy Asthma Proc., 2009, 30, 109-119.
13. Paredi, P.; Barnes, P. J. The airway vasculature: recent advances and clinical implications. Thorax, 2009, 64, 444-450.
14. Nistala, K.; Wedderburn, L. R. Th17 and regulatory T cells: rebalancing pro- and anti- inflammatory forces in autoimmune arthritis. Rheumatology (Oxford), 2009, 48, 602-606.
15. Annunziato, F.; Cosmi, L.; Liotta, F.; Maggi, E.; Romagnani, S. Type 17 T helper cells- origins, features and possible roles in rheumatic disease. Nat. Rev. Rheumatol., 2009, 5, 325-331.
16. Gibbons, L. J.; Hyrich, K. L. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs, 2009, 23, 111-124.
17. Brand, S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut, 2009, 58, 1152-1167.
18. Abraham, C.; Cho, J. H. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu. Rev. Med., 2009, 60, 97-110.
19. Abraham, C.; Cho, J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm. Bowel Dis., 2009, 15, 1090-1100.
20. Braus, N. A.; Elliott, D. E. Advances in the pathogenesis and treatment of IBD. Clin. Immunol., 2009, 132, 1-9.
21. Nestle, F. O.; Kaplan, D. H.; Barker, J. Psoriasis. N. Engl. J. Med., 2009, 361, 496-509.
22. Di Cesare, A.; Di Meglio, P.; Nestle, F. O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 2009, 129, 1339-1350.
23. Naldi, L.; Raho, G. Emerging drugs for psoriasis. Expert Opin. Emerg. Drugs, 2009, 14, 145-163.
24. Rozenblit, M.; Lebwohl, M. New biologics for psoriasis and psoriatic arthritis. Dermatol. Ther., 2009, 22, 56-60.
25. Bennett, J. L.; Stuve, O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin. Neuropharmacol., 2009, 32, 121-132.
26. Giacomini, P. S.; Darlington, P. J.; Bar-Or, A. Emerging multiple sclerosis disease-modifying therapies. Curr. Opin. Neurol., 2009, 22, 226-232.
27. Lopez-Diego, R. S.; Weiner, H. L. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary. Nat. Rev. Drug Discov., 2008, 7, 909-925.
28. Siomi, M. C. Short interfering RNA-mediated gene silencing; towards successful application in human patients. Adv. Drug Deliv. Rev., 2009, 61, 668-671.
29. Juliano, R.; Bauman, J.; Kang, H.; Ming, X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm., 2009, 6, 686-695.
30. Endoh, T.; Ohtsuki, T. Cellular siRNA delivery using cellpenetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev., 2009, 61, 704-709.
31. Venugopal, J.; Prabhakaran, M. P.; Low, S.; Choon, A. T.; Zhang, Y. Z.; Deepika, G.; Ramakrishna, S. Nanotechnology for nanomedicine and delivery of drugs. Curr. Pharm. Des., 2008, 14 2184-2200.
32. Debbage, P. Targeted drugs and nanomedicine: present and future. Curr. Pharm. Des., 2009, 15, 153-172.
33. Singh, R.; Lillard, J. W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86, 215-223.
34. Gao, K.; Huang, L. Nonviral methods for siRNA delivery. Mol. Pharm., 2009, 6, 651-658.
35. Juliano, R.; Alam, M. R.; Dixit, V.; Kang, H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res., 2008, 36, 4158-4171.
36. Howard, K. A. Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv. Drug Deliv. Rev., 2009, 61, 710-720.
37. Goldberg, M.; Langer, R.; Jia, X. Nanostructured materials for applications in drug delivery and tissue engineering. J. Biomater. Sci. Polym. Ed., 2007, 18, 241-268.
38. Sanvicens, N.; Marco, M. P. Multifunctional nanoparticles-- properties and prospects for their use in human medicine. Trends Biotechnol., 2008, 26, 425-433.
39. Sandhiya, S.; Dkhar, S. A.; Surendiran, A. Emerging trends of nanomedicine--an overview. Fundam. Clin. Pharmacol., 2009, 23 263-269.
40. Fattal, E.; Barratt, G. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br. J. Pharmacol., 2009, 157, 179-194.
41. Gaumet, M.; Vargas, A.; Gurny, R.; Delie, F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm., 2008, 69, 1-9.
42. Shi, Y.; Huang, G. Recent developments of biodegradable and biocompatible materials based micro/nanoparticles for delivering macromolecular therapeutics. Crit. Rev. Ther. Drug Carrier Syst., 2009, 26, 29-84.
43. Hillaireau, H.; Couvreur, P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol. Life Sci., 2009, 66, 2873-2896.
44. Pucci, S.; Incorvaia, C. Allergy as an organ and a systemic disease. Clin. Exp. Immunol., 2008, 153( Suppl 1), 1-2.
45. Woodfolk, J. A. The immune response to intrinsic and extrinsic allergens: determinants of allergic disease. Curr. Pharm. Des., 2006, 12, 2349-2363.
46. Kay, A. B. Allergy and allergic diseases: first of two parts. N. Engl. J. Med., 2001, 344, 30-37.
47. Kay, A. B. Allergy and allergic diseases: second of two parts. N. Engl. J. Med., 2001, 344, 109-113.
48. Kay, A.B. Overview of 'allergy and allergic diseases: with a view to the future'. Br. Med. Bull., 2000, 56, 843-864
49. Shakib, F.; Ghaemmaghami, A. M.; Sewell, H. F. The molecular basis of allergenicity. Trends Immunol., 2008, 29, 633-642.
50. Galli, S. J.; Tsai, M.; Piliponsky, A. M. The development of allergic inflammation. Nature, 2008, 454, 445-454.
51. Gould, H. J.; Sutton, B. J. IgE in allergy and asthma today. Nat. Rev. Immunol., 2008, 8, 205-217.
52. Woodfolk, J. A.; Platts-Mills, T. A. T-cell responses to allergens. Int. Arch. Allergy Immunol., 2002, 129, 277-285.
53. Poulsen, L. K.; Hummelshoj, L. Triggers of IgE class switching and allergy development. Ann. Med., 2007, 39, 440-456.
54. Woodfolk, J. A. Cytokines as a therapeutic target for allergic diseases: a complex picture. J. Allergy Clin. Immunol., 2007, 119, 280-294.
55. Pettipher, R. The roles of the prostaglandin D[2]receptors DP[1]and CRTH2 in promoting allergic responses. Br. J. Pharmacol., 2008, 153( Suppl 1), S191-199.
56. Ohnishi, H.; Miyahara, N.; Gelfand, E. W. The role of leukotriene B[4]in allergic diseases. Allergol. Int., 2008, 57, 291-298.
57. Matsuno, O.; Kumamoto, T.; Higuchi, Y. ADAM8 in allergy. Inflamm. Allergy Drug Targets, 2008, 7, 108-112.
58. Bullens, D. M.; Ceuppens, J. L. Influence of Toll-like-receptor ligands on the dendritic cell-T cell interactions: therapeutic options for allergic diseases? Inflamm. Allergy Drug Targets, 2008, 7, 211-216.
59. Wakashin, H.; Hirose, K.; Iwamoto, I.; Nakajima, H. Role of IL- 23-Th17 cell axis in allergic airway inflammation. Int. Arch. Allergy Immunol., 2009, 149(Suppl 1), 108-112.
60. Schmidt-Weber, C. B. Th17 and treg cells innovate the TH1/TH2 concept and allergy research. Chem. Immunol. Allergy, 2008, 94, 1-7.
61. Wang, Y. H.; Liu, Y. J. The IL-17 cytokine family and their role in allergic inflammation. Curr. Opin. Immunol., 2008, 20, 697-702.
62. Oboki, K.; Ohno, T.; Saito, H.; Nakae, S. Th17 and allergy. Allergol. Int., 2008, 57, 121-134.
63. Nouri-Aria, K. T.; Durham, S. R. Regulatory T cells and allergic disease. Inflamm. Allergy Drug Targets, 2008, 7, 237-252.
64. Akdis, C.A.; Akdis, M:Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. Clin. Exp. Allergy, 2009, 123, 735-746.
65. Ogawa, Y.; Duru, E. A.; Ameredes, B. T. Role of IL-10 in the resolution of airway inflammation. Curr. Mol. Med., 2008, 8, 437-445.
66. Kolls, J. K.; Kanaly, S. T.; Ramsay, A. J. Interleukin-17: an emerging role in lung inflammation. Am. J. Respir. Cell Mol. Biol., 2003, 28, 9-11.
67. Schwarzenberger, P.; La Russa, V.; Miller, A.; Ye, P.; Huang, W.; Zieske, A.; Nelson, S.; Bagby, G. J.; Stoltz, D.; Mynatt, R. L.; Spriggs, M.; Kolls, J. K. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J. Immunol., 1998, 161, 6383-6389.
68. Laan, M.; Cui, Z. H.; Hoshino, H.; Lotvall, J.; Sjostrand, M.; Gruenert, D. C.; Skoogh, B. E.; Linden, A. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 1999, 162, 2347-2352.
69. Nakae, S.; Komiyama, Y.; Nambu, A.; Sudo, K.; Iwase, M.; Homma, I.; Sekikawa, K.; Asano, M.; Iwakura, Y. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity, 2002, 17, 375-387.
70. Schnyder-Candrian, S.; Togbe, D.; Couillin, I.; Mercier, I.; Brombacher, F.; Quesniaux, V.; Fossiez, F.; Ryffel, B.; Schnyder, B. Interleukin- 17 is a negative regulator of established allergic asthma. J. Exp. Med., 2006, 203, 2715-2725.
71. Angkasekwinai, P.; Park, H.; Wang, Y. H.; Wang, Y. H.; Chang, S. H.; Corry, D. B.; Liu, Y. J.; Zhu, Z.; Dong, C. Interleukin 25 promotes the initiation of proallergic type 2 responses. J. Exp. Med., 2007, 204, 1509-1517.
72. Wang, Y. H.; Angkasekwinai, P.; Lu, N.; Voo, K. S.; Arima, K.; Hanabuchi, S.; Hippe, A.; Corrigan, C. J.; Dong, C.; Homey, B.; Yao, Z.; Ying, S.; Huston, D. P.; Liu, Y. J. IL- 25 augments type 2 immune responses by enhancing the expansion and functions of bTSLP-DC-activated Th2 memory cells. J. Exp. Med., 2007, 204, 1837-1847.
73. Fort, M. M.; Cheung, J.; Yen, D.; Li, J.; Zurawski, S. M.; Lo, S.; Menon, S.; Clifford, T.; Hunte, B.; Lesley, R.; Muchamuel, T.; Hurst, S. D.; Zurawski, G.; Leach, M. W.; Gorman, D. M.; Rennick, D. M. IL-25 induces IL-4, IL-5, and IL-13 and Th2- associated pathologies in vivo. Immunity, 2001, 15, 985-995.
74. Kim, M. R.; Manoukian, R.; Yeh, R.; Silbiger, S. M.; Danilenko, D. M.; Scully, S.; Sun, J.; DeRose, M. L.; Stolina, M.; Chang, D.; Van, G. Y.; Clarkin, K.; Nguyen, H. Q.; Yu, Y. B.; Jing, S.; Senaldi, G.; Elliott, G.; Medlock, E. S. Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood, 2002, 100, 2330-2340.
75. Hurst, S. D.; Muchamuel, T.; Gorman, D. M.; Gilbert, J. M.; Clifford, T.; Kwan, S.; Menon, S.; Seymour, B.; Jackson, C.; Kung, T. T.; Brieland, J. K.; Zurawski, S. M.; Chapman, R. W.; Zurawski, G.; Coffman, R. L. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J. Immunol., 2002, 169, 443-453.
76. Pan, G.; French, D.; Mao, W.; Maruoka, M.; Risser, P.; Lee, J.; Foster, J.; Aggarwal, S.; Nicholes, K.; Guillet, S.; Schow, P.; Gurney, A. L. Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J. Immunol., 2001, 167, 6559-6567.
77. Ballantyne, S. J.; Barlow, J. L.; Jolin, H. E.; Nath, P.; Williams, A. S.; Chung, K. F.; Sturton, G.; Wong, S. H.; McKenzie, A. N:. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J. Allergy Clin. Immunol., 2007, 120, 1324-1331.
78. Tamachi, T.; Maezawa, Y.; Ikeda, K.; Kagami, S.; Hatano, M.; Seto, Y.; Suto, A.; Suzuki, K.; Watanabe, N.; Saito, Y.; Tokuhisa, T.; Iwamoto, I.; Nakajima, H. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. J. Allergy Clin. Immunol., 2006, 118, 606-614.
79. Orihara, K.; Narita, M.; Tobe, T.; Akasawa, A.; Ohya, Y.; Matsumoto, K.; Saito, H. Circulating Foxp3+CD4+ cell numbers in atopic patients and healthy control subjects. J. Allergy Clin. Immunol., 2007, 120, 960-962.
80. Nguyen, K. D.; Fohner, A.; Booker, J. D.; Dong, C.; Krensky, A. M.; Nadeau, K. C. XCL1 enhances regulatory activities of CD4+ CD25[high]CD127[low/-] T cells in human allergic asthma. J. Immunol., 2008, 181, 5386-5395.
81. Verhagen, J.; Akdis, M.; Traidl-Hoffmann, C.; Schmid- Grendelmeier, P.; Hijnen, D.; Knol, E. F.; Behrendt, H.; Blaser, K.; Akdis, C. A. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J. Allergy Clin. Immunol., 2006, 117, 176-183.
82. Jartti, T.; Burmeister, K. A.; Seroogy, C. M.; Jennens-Clough, M. L.; Tisler, C. J.; Salazar, L. P.; Dasilva, D. F.; Evans, M. D.; Vrtis, R. F.; Wallace, P. K.; Ruiz-Perez, B.; Gangnon, R. E.; Lemanske, R. F.,Jr; Gern, J. E. Association between CD4[+]CD25[high] T cells and atopy in children. J. Allergy Clin. Immunol., 2007, 120, 177-183.
83. Fontenot, J. D.; Gavin, M. A.; Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol., 2003, 4, 330-336.
84. Lewkowich, I. P.; Herman, N. S.; Schleifer, K. W.; Dance, M. P.; Chen, B. L.; Dienger, K. M.; Sproles, A. A.; Shah, J. S.; Kohl, J.; Belkaid, Y.; Wills-Karp, M. CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J. Exp. Med., 2005, 202, 1549-1561.
85. Strickland, D. H.; Stumbles, P. A.; Zosky, G. R.; Subrata, L. S.; Thomas, J. A.; Turner, D. J.; Sly, P. D.; Holt, P. G. Reversal of airway hyperresponsiveness by induction of airway mucosal CD4+CD25+ regulatory T cells. J. Exp. Med., 2006, 203, 2649-2660.
86. Wilson, M. S.; Pesce, J. T.; Ramalingam, T. R.; Thompson, R. W.; Cheever, A.; Wynn, T. A. Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells. J. Immunol., 2008, 181, 6942-6954.
87. Curotto de Lafaille, M. A.; Kutchukhidze, N.; Shen, S.; Ding, Y.; Yee, H.; Lafaille, J. J. Adaptive Foxp3+ regulatory T celldependent and -independent control of allergic inflammation. Immunity, 2008, 29, 114-126.
88. Lohr, J.; Knoechel, B.; Abbas, A. K. Regulatory T cells in the periphery. Immunol. Rev., 2006, 212, 149-162.
89. Gri, G.; Piconese, S.; Frossi, B.; Manfroi, V.; Merluzzi, S.; Tripodo, C.; Viola, A.; Odom, S.; Rivera, J.; Colombo, M. P.; Pucillo, C.E. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity, 2008, 29, 771-781.
90. Rolland, J. M.; Gardner, L. M.; O'Hehir, R. E. Allergen-related approaches to immunotherapy. Pharmacol. Ther., 2009, 121, 273-284.
91. Ozdemir, C.; Akdis, M.; Akdis, C. A. T regulatory cells and their counterparts: masters of immune regulation. Clin. Exp. Allergy, 2009, 39, 626-639.
92. Akdis, M.; Akdis, C. A. Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol., 2007, 119, 780-791.
93. Francis, J. N.; Till, S. J.; Durham, S. R. Induction of IL- 10+CD4+CD25+ T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol., 2003, 111, 1255-1261.
94. Gardner, L. M.; Thien, F. C.; Douglass, J. A.; Rolland, J. M.; O'Hehir, R. E. Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin- 10+ T cells expressing peripheral tissue trafficking markers. Clin. Exp. Allergy, 2004, 34, 1209-1219.
95. Pereira-Santos, M. C.; Baptista, A. P.; Melo, A.; Alves, R. R.; Soares, R. S.; Pedro, E.; Pereira-Barbosa, M.; Victorino, R. M.; Sousa, A. E. Expansion of circulating Foxp3+] CD25 bright CD4+ T cells during specific venom immunotherapy. Clin. Exp. Allergy 2008, 38, 291-297.
96. Carnes, J.; Robinson, D. S. New strategies for allergen immunotherapy. Recent. Pat. Inflamm. Allergy Drug Discov., 2008, 2, 92-101.
97. Scholl, I.; Boltz-Nitulescu, G.; Jensen-Jarolim, E. Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J. Control. Release, 2005, 104, 1-27.
98. Velickovic, T. C.; Jankov, R. M. Design and modifications of allergens for improving specific immunotherapy. Inflamm. Allergy Drug Targets, 2008, 7, 270-278.
99. Akdis M. Immune tolerance in allergy. Curr. Opin. Immunol., 2009, 21(6): 700-707.
100. Akdis, M.; Akdis, C.A. Therapeutic manipulation of immune tolerance in allergic disease. Nat. Rev. Drug Discov., 2009, 8, 645-660.
101. Scholl, I.; Kopp, T.; Bohle, B.; Jensen-Jarolim, E. Biodegradable PLGA particles for improved systemic and mucosal treatment of Type I allergy. Immunol. Allergy Clin. North. Am., 2006, 26, 349-364.
102. O'Hagan, D. T.; Palin, K.; Davis, S. S.; Artursson, P.; Sjoholm, I. Microparticles as potentially orally active immunological adjuvants. Vaccine, 1989, 7, 421-424.
103. Roth-Walter, F.; Scholl, I.; Untersmayr, E.; Fuchs, R.; Boltz- Nitulescu, G.; Weissenbock, A.; Scheiner, O.; Gabor, F.; Jensen- Jarolim, E. M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. J. Allergy Clin. Immunol., 2004, 114, 1362-1368.
104. Walter, F.; Scholl, I.; Untersmayr, E.; Ellinger, A.; Boltz-Nitulescu, G.; Scheiner, O.; Gabor, F.; Jensen-Jarolim, E. Functionalisation of allergen-loaded microspheres with wheat germ agglutinin for targeting enterocytes. Biochem. Biophys. Res. Commun., 2004, 315, 281-287.
105. Tabata, Y.; Ikada, Y. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. J. Biomed. Mater. Res., 1988, 22, 837-858.
106. Newman, K. D.; Elamanchili, P.; Kwon, G. S.; Samuel, J. Macrophage phagocytosis of biodegradable microspheres composed of Llactic acid/glycolic acid homo- and copolymers. J. Biomed. Mater. Res., 2002, 60, 480-486.
107. Waeckerle-Men, Y.; Allmen, E. U.; Gander, B.; Scandella, E.; Schlosser, E.; Schmidtke, G.; Merkle, H. P.; Groettrup, M. Encapsulation of proteins and peptides into biodegradable poly[D,Llactide- co-glycolide] microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine, 2006, 24, 1847-1857.
108. Jilek, S.; Merkle, H. P.; Walter, E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv. Drug Deliv. Rev., 2005, 57, 377-390.
109. Lutsiak, M. E.; Robinson, D. R.; Coester, C.; Kwon, G. S.; Samuel, J. Analysis of poly[D,L-lactic-co-glycolic acid]nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res., 2002, 19, 1480-1487.
110. Eldridge, J. H.; Staas, J. K.; Meulbroek, J. A.; McGhee, J. R.; Tice, T. R.; Gilley, R. M. Biodegradable microspheres as a vaccine delivery system. Mol. Immunol., 1991, 28, 287-294.
111. O'Hagan, D. T.; Rahman, D.; McGee, J.P.; Jeffery, H.; Davies, M.C.; Williams, P.; Davis, S. S.; Challacombe, S. J. Biodegradable microparticles as controlled release antigen delivery systems. Immunology, 1991, 73, 239-242.
112. Challacombe, S. J.; Rahman, D.; Jeffery, H.; Davis, S. S.; O'Hagan, D. T. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology, 1992, 76, 164-168.
113. O'Hagan, D. T.; Jeffery, H.; Davis, S. S. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine, 1993, 11, 965-969.
114. Maloy, K. J.; Donachie, A. M.; O'Hagan, D. T.; Mowat, A. M. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly[lactide-coglycolide] microparticles. Immunology, 1994, 81, 661-667.
115. O'Hagan, D. T.; Jeffery, H.; Maloy, K. J.; Mowat, A. M.; Rahman, D.; Challacombe, S: Biodegradable microparticles as oral vaccines. J. Adv. Exp. Med. Biol., 1995, 371B, 1463-1467.
116. Calvo, P.; Remuñan-López, C.; Vila-Jato, J.L.; Alonso, M.J. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm. Res., 1997, 14, 1431-1436.
117. Bacon, A.; Makin, J.; Sizer, P. J.; Jabbal-Gill, I.; Hinchcliffe, M.; Illum, L; Chatfield, S.; Roberts, M. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect. Immun., 2000, 68, 5764-5770.
118. Illum, L.; Jabbal-Gill, I.; Hinchcliffe, M.; Fisher, A.N.; Davis, S.S. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev., 2001, 51, 81-96.
119. van der Lubben, I. M.; Verhoef, J. C.; Borchard, G.; Junginger, H. E. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev., 2001, 52, 139-144.
120. Illum, L.; Jabbal-Gill, I.; Hinchcliffe, M.; Fisher, A. N.; Davis, S. S. Chitosan as a novel nasal delivery system for vaccines Adv. Drug Deliv. Rev., 2001, 51, 81-96.
121. Singh, M.; Chakrapani, A.; O'Hagan, D. Nanoparticles and microparticles as vaccine- delivery systems. Expert Rev. Vaccines, 2007, 6, 797-808.
122. Johansen, P.; Martinez Gomez, J. M.; Gander, B. Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. Expert Rev. Vaccines, 2007, 6, 471-474.
123. Fahmy, T. M.; Demento, S. L.; Caplan, M. J.; Mellman, I.; Saltzman, W. M. Design opportunities for actively targeted nanoparticle vaccines. Nanomed, 2008, 3, 343-355.
124. Marcato, P. D.; Duran, N. New aspects of nanopharmaceutical delivery systems. J. Nanosci. Nanotechnol., 2008, 8, 2216-2229.
125. Masotti, A.; Ortaggi, G. Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery. Mini Rev. Med. Chem., 2009, 9, 463-469.
126. Krishnamachari, Y.; Salem, A. K. Innovative strategies for codelivering antigens and CpG oligonucleotides. Adv. Drug Deliv. Rev., 2009, 61, 205-217.
127. Kreuter, J.; Liehl, E. Long-term studies of microencapsulated and adsorbed influenza vaccine nanoparticles. J. Pharm. Sci., 1981, 70, 367-371.
128. Michalek, S. M.; Childers, N. K.; Katz, J.; Denys, F. R.; Berry, A. K.; Eldridge, J. H.; McGhee, J. R.; Curtiss, R: Liposomes as oral adjuvants. Curr. Top. Microbiol. Immunol., 1989, 146, 51-58.
129. Salman, H. H.; Irache, J. M.; Gamazo, C. Immunoadjuvant capacity of flagellin and mannosamine-coated poly[anhydride] nanoparticles in oral vaccination. Vaccine, 2009, 27, 4784-4790.
130. Demento, S. L.; Eisenbarth, S. C.; Foellmer, H. G.; Platt, C.; Caplan, M. J.; Mark Saltzman, W.; Mellman, I.; Ledizet, M.; Fikrig, E.; Flavell, R. A.; Fahmy, T. M. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine, 2009, 27, 3013-3021.
131. Sharp, F. A.; Ruane, D.; Claass, B.; Creagh, E.; Harris, J.; Malyala, P.; Singh, M.; O'Hagan, D. T.; Petrilli, V.; Tschopp, J.; O'Neill, L. A.; Lavelle, E. C. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. USA, 2009, 106, 870-875.
132. Malyala, P.; O'Hagan, D. T.; Singh, M. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Adv. Drug Deliv. Rev., 2009, 61, 218-225.
133. Malyala, P.; Chesko, J.; Ugozzoli, M.; Goodsell, A.; Zhou, F.; Vajdy, M.; O'Hagan, D. T.; Singh, M. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm. Sci., 2008, 97, 1155-1164.
134. Beaudette, T. T.; Bachelder, E. M.; Cohen, J. A.; Obermeyer, A. C.; Broaders, K. E.; Frechet, J. M.; Kang, E. S.; Mende, I.; Tseng, W. W.; Davidson, M. G.; Engleman, E. G. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in aciddegradable microparticle vaccines. Mol. Pharm., 2009, 6, 1160-1169.
135. Krishnamachari, Y.; Salem, A.K. Innovative strategies for codelivering antigens and CpG oligonucleotides. Adv. Drug Deliv. Rev., 2009, 28, 205-217.
136. Chikh, G.; de Jong, S. D.; Sekirov, L.; Raney, S. G.; Kazem, M.; Wilson, K. D.; Cullis, P. R.; Dutz, J. P.; Tam, Y. K. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int. Immunol., 2009, 21, 757-767.
137. Zhang, X. Q.; Intra, J.; Salem, A. K. Comparative study of poly [lactic-co-glycolic acid]- poly ethyleneimine-plasmid DNA microparticles prepared using double emulsion methods. J. Microencapsul., 2008, 25, 1-12.
138. Takagi, I.; Nishimura, J.; Itoh, H.; Baba, S.; Kunimatsu, M.; Sasaki, M. Poly [lactic/glycolic acid]microspheres containing antigen as a novel and potential agent of immunotherapy for allergic disorders. Arerugi, 1992, 41, 1388-1397.
139. Matsunaga, Y.; Wakatsuki, Y.; Tabata, Y.; Kawasaki, H.; Usui, T.; Yoshida, M.; Itoh, T.; Habu, S.; Kita, T. Oral immunization with size-purified microsphere beads as a vehicle selectively induces systemic tolerance and sensitization. Vaccine, 2000, 19, 579-588.
140. San Roman, B.; Irache, J. M.; Gomez, S.; Gamazo, C.; Espuelas, S. Co-delivery of ovalbumin and CpG motifs into microparticles protected sensitized mice from anaphylaxis. Int. Arch. Allergy Immunol., 2009, 149, 111-118.
141. Gomez, S.; Gamazo, C.; San Roman, B.; Ferrer, M.; Sanz, M. L.; Espuelas, S.; Irache, J. M Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis. Eur. J. Pharm. Biopharm., 2008, 70, 711-717.
142. Quiralte, J.; Palacios, L.; Rodriguez, R.; Cardaba, B.; Arias de Saavedra, J. M.; Villalba, M.; Florido, J. F.; Lahoz, C. Modeling diseases: the allergens of Olea europaea pollen. J. Investig. Allergol. Clin. Immunol., 2007, 17(Suppl 1), 24-30.
143. Barber, D.; de la Torre, F.; Feo, F.; Florido, F.; Guardia, P.; Moreno, C.; Quiralte, J.; Lombardero, M.; Villalba, M.; Salcedo, G.; Rodriguez, R. Understanding patient sensitization profiles in complex pollen areas: a molecular epidemiological study. Allergy, 2008, 63, 1550-1558.
144. Igartua, M.; Hernandez, R. M.; Gutierro, I.; Gascon, A. R.; Pedraz, J. L. Preliminary assessment of the immune response to Olea europaea pollen extracts encapsulated into PLGA microspheres. Pharm. Dev. Technol., 2001, 6, 621-627.
145. Batanero, E.; Barral, P.; Villalba, M.; Rodriguez, R. Biodegradable poly [DL-lactide glycolide]microparticles as a vehicle for allergenspecific vaccines: a study performed with Ole e 1, the main allergen of olive pollen. J. Immunol. Methods, 2002, 259, 87-94.
146. Batanero, E.; Barral, P.; Villalba, M.; Rodriguez, R. Encapsulation of Ole e 1 in biodegradable microparticles induces Th1 response in mice: a potential vaccine for allergy. J. Control. Release, 2003, 92, 395-398.
147. Marazuela, E. G.; Prado, N.; Moro, E.; Fernandez-Garcia, H.; Villalba, M.; Rodriguez, R.; Batanero, E. Intranasal vaccination with poly[lactide-co- glycolide] microparticles containing a peptide T of Ole e 1 prevents mice against sensitization. Clin. Exp. Allergy, 2008, 38, 520-528.
148. Scholl, I.; Weissenbock, A.; Forster-Waldl, E.; Untersmayr, E.; Walter, F.; Willheim, M.; Boltz-Nitulescu, G.; Scheiner, O.; Gabor, F.; Jensen-Jarolim, E. Allergen-loaded biodegradable poly[D,Llactic- co-glycolic]acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model. Clin. Exp. Allergy, 2004, 34, 315-321.
149. Roth-Walter, F.; Scholl, I.; Untersmayr, E.; Ellinger, A.; Boltz- Nitulescu, G.; Scheiner, O.; Gabor, F.; Jensen-Jarolim, E. Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine, 2005, 23, 2703-2710.
150. Schöll, I.; Kopp, T.; Bohle, B.; Jensen-Jarolim, E. Biodegradable PLGA particles for improved systemic and mucosal treatment of Type I allergy. Immunol. Allergy Clin. North Am., 2006, 26, 349-364.
151. Gómez, S.; Gamazo, C.; San Roman, B.; Grau, A.; Espuelas, S.; Ferrer, M.; Sanz, M.L.; Irache, J.M. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne. J. Immunol. Methods, 2009, 348, 1-8.
152. Arias, K.; Waserman, S.; Jordana, M. Management of food-induced anaphylaxis: unsolved challenges. Curr. Clin. Pharmacol., 2009, 4, 113-125.
153. Sicherer, S. H.; Leung, D. Y. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2008. J. Allergy Clin. Immunol., 2009, 123, 319-327.
154. Larche, M.; Akdis, C. A.; Valenta, R. Immunological mechanisms of allergen-specific immunotherapy Nat. Rev. Immunol., 2006, 6, 761-771.
155. Burks, A. W.; Laubach, S.; Jones, S. M. Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J. Allergy Clin. Immunol., 2008, 121, 1344-1350
156. Skripak, J. M.; Sampson, H. A. Towards a cure for food allergy. Curr. Opin. Immunol., 2008, 20, 690-696.
157. Beyer, K.; Wahn, U. Oral immunotherapy for food allergy in children. Curr. Opin. Allergy Clin. Immunol., 2008, 8, 553-556.
158. Pecquet, S.; Leo, E.; Fritsche, R.; Pfeifer, A.; Couvreur, P.; Fattal, E. Oral tolerance elicited in mice by beta-lactoglobulin entrapped in biodegradable microspheres. Vaccine, 2000, 18,1196-1202.
159. Fattal, E.; Pecquet, S.; Couvreur, P.; Andremont, A. Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens. Int. J. Pharm., 2002, 242, 15-24.
160. Burks, A.W. Peanut allergy. Lancet 2008, 371, 1538-1546.
161. Roy, K.; Mao, H. Q.; Huang, S. K.; Leong, K. W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med., 1999, 5, 387-391.
162. Diwakar, L.; Noorani, S.; Huissoon, A. P.; Frew, A. J.; Krishna, M. T. Practice of venom immunotherapy in the United Kingdom: a national audit and review of literature. Clin. Exp. Allergy, 2008, 38, 1651-1658.
163. Long, A. A.; Camargo, C. A. Current practice of venom immunotherapy in the UK. Clin. Exp. Allergy, 2008, 38, 1576-1578.
164. Guerin, V.; Dubarryr, M.; Robic, D.; Brachet, F.; Rautureau, M.; Andre, C.; Bourbouze, R.; Tome, D. Microsphere entrapped beevenom phospholipase A2 retains specific IgE binding capacity: a possible use for oral specific immunotherapy. J. Microencapsul., 2002, 19, 761-765.
165. Jilek, S.; Walter, E.; Merkle, H. P.; Corthesy, B. Modulation of allergic responses in mice by using biodegradable poly[lactide-coglycolide] microspheres. J. Allergy Clin. Immunol., 2004, 114, 943-950.
166. Martinez Gomez, J. M.; Fischer, S.; Csaba, N.; Kundig, T. M.; Merkle, H. P.; Gander, B.; Johansen, P. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm. Res., 2007, 24, 1927-1935.
167. Pison, U.; Welte, T.; Giersig, M.; Groneberg, D. A. Nanomedicine for respiratory diseases. Eur. J. Pharmacol., 2006, 533, 341-350.
168. Card, J. W.; Zeldin, D. C.; Bonner, J. C.; Nestmann, E. R. Pulmonary applications and toxicity of engineered nanoparticles. Am. J. Physiol. Lung Cell Mol. Physiol., 2008, 295, 400-411.
169. Sung, J. C.; Pulliam, B. L.; Edwards, D. A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol., 2007, 25, 563-570.
170. Buxton, D. B. Nanomedicine for the management of lung and blood diseases. Nanomed, 2009, 4, 331-339.
171. Hammad, H.; Lambrecht, B. N. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat. Rev. Immunol., 2008, 8, 193-204. (Pubitemid 351323293)
172. Afshar, R.; Medoff, B. D.; Luster, A. D. Allergic asthma: a tale of many T cells. Clin. Exp. Allergy, 2008, 38, 1847-1857.
173. Passalacqua, G.; Ciprandi, G. Allergy and the lung. Clin. Exp. Immunol., 2008, 153 (Suppl.1), 12-16.
174. Nauta, A. J.; Engels, F.; Knippels, L. M.; Garssen, J.; Nijkamp, F. P.; Redegeld, F. A. Mechanisms of allergy and asthma. Eur. J. Pharmacol., 2008, 585, 354-360.
175. Anderson, G. P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet, 2008, 372, 1107-1119.
176. Hung, L. Y.; Velichko, S.; Huang, F.; Thai, P.; Wu, R. Regulation of airway innate and adaptive immune responses: the IL-17 paradigm. Crit. Rev. Immunol., 2008, 28, 269-279.
177. Barnes, P. J. The cytokine network in asthma and chronic obstructive pulmonary disease. J. Clin. Invest., 2008, 118, 3546-3556.
178. Holgate, S. T.; Polosa, R. Treatment strategies for allergy and asthma. Nat. Rev. Immunol., 2008, 8, 218-230.
179. Adcock, I. M.; Caramori, G.; Chung, K. F. New targets for drug development in asthma. Lancet, 2008, 372, 1073-1087.
180. Neimert-Andersson, T.; Thunberg, S.; Swedin, L.; Wiedermann, U.; Jacobsson-Ekman, G.; Dahlen, S. E.; Scheynius, A.; Gronlund, H.; van Hage, M.; Gafvelin, G. Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Allergy, 2008, 63, 518-526.
181. Thunberg, S.; Neimert-Andersson, T.; Cheng, Q.; Wermeling, F.; Bergstrom, U.; Swedin, L.; Dahlen, S. E.; Arner, E.; Scheynius, A.; Karlsson, M. C.; Gafvelin, G.; van Hage, M.; Gronlund, H. Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice. Allergy, 2009, 64, 919-926.
182. Li, J.; Liu, Z.; Wu, Y.; Wu, H.; Ran, P. Chitosan microparticles loaded with mite group 2 allergen Der f 2 alleviate asthma in mice. J. Investig. Allergol. Clin. Immunol., 2008, 18, 454-460.
183. Chew, J. L.; Wolfowicz, C. B.; Mao, H. Q.; Leong, K. W.; Chua, K. Y. Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine, 2003, 21, 2720-2729.
184. Li, G. P.; Liu, Z. G.; Liao, B.; Zhong, N. S. Induction of Th1-type immune response by chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen Der p 2 for oral vaccination in mice. Cell Mol. Immunol., 2009, 6, 45-50.
185. Saint-Lu, N.; Tourdot, S.; Razafindratsita, A.; Mascarell, L.; Berjont, N.; Chabre, H.; Louise, A.; Van Overtvelt, L.; Moingeon, P. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy, 2009, 64, 1003-1013.
186. Ryan, J. J.; Bateman, H. R.; Stover, A.; Gomez, G.; Norton, S. K.; Zhao, W.; Schwartz, L. B.; Lenk, R.; Kepley, C. L. Fullerene nanomaterials inhibit the allergic response. J. Immunol., 2007, 179, 665-672.
187. Onizawa, S.; Aoshiba, K.; Kajita, M.; Miyamoto, Y.; Nagai, A. Platinum nanoparticle antioxidants inhibit pulmonary inflammation in mice exposed to cigarette smoke. Pulm. Pharmacol. Ther., 2009, 22, 340-349.
188. Shibata, Y.; Honda, I.; Justice, J. P.; Van Scott, M. R.; Nakamura, R. M.; Myrvik, Q. N. Th1 adjuvant N-acetyl-D-glucosamine polymer up-regulates Th1 immunity but down- regulates Th2 immunity against a mycobacterial protein [MPB-59] in interleukin- 10-knockout and wild-type mice. Infect. Immun., 2001, 69, 6123-6130.
189. Shibata, Y.; Foster, L. A.; Bradfield, J. F.; Myrvik, Q. N. Oral administration of chitin down-regulates serum IgE levels and lung eosinophilia in the allergic mouse. J. Immunol., 2000, 164, 1314-1321.
190. Strong, P.; Clark, H.; Reid, K. Intranasal application of chitin microparticles down- regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy. Clin. Exp. Allergy, 2002, 32, 1794-1800.
191. Ozdemir, C.; Yazi, D.; Aydogan, M.; Akkoc, T.; Bahceciler, N. N.; Strong, P.; Barlan, I. B. Treatment with chitin microparticles is protective against lung histopathology in a murine asthma model. Clin. Exp. Allergy, 2006, 36, 960-968.
192. Lee, D. W.; Shirley, S. A.; Lockey, R. F.; Mohapatra, S. S. Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline. Respir. Res., 2006, 7, 112.
193. Matsuo, Y.; Ishihara, T.; Ishizaki, J.; Miyamoto, K. I.; Higaki, M.; Yamashita, N. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol., 2009, 260(1), 33-38.
194. Wang, X.; Xu, W.; Kong, X.; Chen, D.; Hellermann, G.; Ahlert, T. A.; Giaimo, J. D.; Cormier, S. A.; Li, X.; Lockey, R. F.; Mohapatra, S.; Mohapatra, S. S. Modulation of lung inflammation by ves sel dilator in a mouse model of allergic asthma. Respir. Res., 2009, 10, 66-74.
195. Kumar, M.; Kong, X.; Behera, A. K.; Hellermann, G. R.; Lockey, R. F.; Mohapatra, S. S. Chitosan IFN-gamma-pDNA nanoparticle [CIN] therapy for allergic asthma. Genet. Vaccines Ther., 2003, 1, 3-13.
196. John, A. E.; Lukacs, N. W.; Berlin, A. A.; Palecanda, A.; Bargatze, R. F.; Stoolman, L. M.; Nagy, J. O. Discovery of a potent nanoparticle P-selectin antagonist with anti- inflammatory effects in allergic airway disease. FASEB J., 2003, 17, 2296-2298.
197. Rossi, B.; Constantin, G. Anti-selectin therapy for the treatment of inflammatory diseases. Inflamm. Allergy Drug Targets, 2008, 7, 85-93.
198. Woodside, D. G.; Vanderslice, P. Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease. BioDrugs, 2008, 22, 85-100.
199. Kimura, S.; Egashira, K.; Chen, L.; Nakano, K.; Iwata, E.; Miyagawa, M.; Tsujimoto, H.; Hara, K.; Morishita, R.; Sueishi, K.; Tominaga, R.; Sunagawa, K. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotalineinduced pulmonary arterial hypertension. Hypertension 2009, 53, 877-883.
200. Fraser, C. C. G protein-coupled receptor connectivity to NFkappaB in inflammation and cancer. Int. Rev. Immunol., 2008, 27, 320-350.
201. Atassi, M. Z.; Casali, P. Molecular mechanisms of autoimmunity. Autoimmunity, 2008, 41, 123-132.
202. Dardalhon, V.; Korn, T.; Kuchroo, V. K.; Anderson, A. C. Role of Th1 and Th17 cells in organ-specific autoimmunity. J. Autoimmun., 2008, 31, 252-256.
203. Ouyang, W.; Kolls, J. K.; Zheng, Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity, 2008, 28, 454-467.
204. Mills, K. H. Induction, function and regulation of IL-17-producing T cells. Eur. J. Immunol., 2008, 38, 2636-2649.
205. Martinez, G. J.; Nurieva, R. I.; Yang, X. O.; Dong, C. Regulation and function of proinflammatory TH17 cells. Ann. N. Y. Acad. Sci., 2008, 1143, 188-211.
206. Korn, T.; Bettelli, E.; Oukka, M.; Kuchroo, V. K. IL-17 and Th17 Cells. Annu. Rev. Immunol., 2009, 27, 485-517.
207. Miossec, P.; Korn, T.; Kuchroo, V. K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med., 2009, 361, 888-898.
208. Allam, R.; Anders, H. J. The role of innate immunity in autoimmune tissue injury. Curr. Opin. Rheumatol., 2008, 20, 538-544.
209. Pisetsky, D. S: The role of innate immunity in the induction of autoimmunity. Autoimmun. Rev., 2008, 8, 69-72.
210. Li, M.; Zhou, Y.; Feng, G.; Su, S. B. The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases. Curr. Mol. Med., 2009, 9, 365-374.
211. Gaffen, S. L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol., 2009, 9, 556-567.
212. Commins, S.; Steinke, J. W.; Borish, L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J. Allergy Clin. Immunol., 2008, 121, 1108-1111.
213. Goriely, S.; Cavoy, R.; Goldman, M. Interleukin-12 family members and type I interferons in Th17-mediated inflammatory disorders. Allergy 2009, 64, 702-709.
214. Gee, K.; Guzzo, C.; Che Mat, N. F.; Ma, W.; Kumar, A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm. Allergy Drug Targets, 2009, 8, 40-52.
215. O'Neill, L. A. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol. Rev., 2008, 226, 10-18.
216. Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol., 2009, 27, 519-550.
217. Croft, M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol., 2009, 9, 271-285.
218. Hamilton, J. A.; Tak, P. P. The dynamics of macrophageineage populations in inflammatory and autoimmune diseases. Arthritis Rheum., 2009, 60, 1210-1221.
219. Blanco, P.; Palucka, A. K.; Pascual, V.; Banchereau, J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev., 2008, 19, 41-52.
220. Rutella, S.; De Cristofaro, R.; Ferraccioli, G. Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Hum. Immunol., 2009, 70, 360-373
221. Johnson-Huang, L. M.; McNutt, N. S.; Krueger, J. G.; Lowes, M. A. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J. Clin. Immunol., 2009, 29, 247-256.
222. Smith, D. J.; Vainio, P. J.Targeting vascular adhesion protein-1 to treat autoimmune and inflammatory diseases. Ann. N. Y. Acad. Sci., 2007, 1110, 382-388.
223. Lawson, C.; Wolf, S. ICAM-1 signaling in endothelial cells. Pharmacol. Rep., 2009, 61, 22-32.
224. Di Cesare, A.; Di Meglio, P.; Nestle, F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol., 2009, 129, 1339-1350.
225. Brand, S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut, 2009, 58, 1152-1167.
226. Maloy, K. The Interleukin-23 / Interleukin-17 axis in intestinal inflammation. J. Intern. Med., 2008, 263, 584-590.
227. Brennan, F. M.; McInnes, I. B. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest., 2008, 118, 3537-3545.
228. Andersson, A. K.; Li, C.; Brennan, F. M: Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Res. Ther., 2008, 10, 204-213.
229. Johnson-Huang, L.M.; McNutt, N.S.; Krueger, J.G.; Lowes, M.A. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J. Clin. Immunol., 2009, 29, 247-256.
230. Xavier, R. J.; Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature, 2007, 448, 427-434.
231. Imboden, J. B. The immunopathogenesis of rheumatoid arthritis. Annu. Rev. Pathol., 2009, 4, 417-434.
232. Necela, B. M.; Cidlowski, J. A. Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc. Am. Thorac. Soc., 2004, 1, 239-246.
233. Schacke, H.; Docke, W. D.; Asadullah, K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther., 2002, 96, 23-43.
234. Horisawa, E.; Hirota, T.; Kawazoe, S.; Yamada, J.; Yamamoto, H.; Takeuchi, H.; Kawashima, Y. Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm. Res., 2002, 19, 403-410.
235. Higaki, M.; Ishihara, T.; Izumo, N.; Takatsu, M.; Mizushima, Y. Treatment of experimental arthritis with poly[D, L-lactic/glycolic acid] nanoparticles encapsulating betamethasone sodium phosphate. Ann. Rheum. Dis. 2005, 64, 1132-1136.
236. Ishihara, T.; Kubota, T.; Choi, T.; Higaki, M. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J. Pharmacol. Exp. Ther., 2009, 329, 412-417.
237. Hwang, J.; Rodgers, K.; Oliver, J. C.; Schluep, T. Alphamethylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int. J. Nanomed., 2008, 3, 359-371.
238. Joner, M.; Morimoto, K.; Kasukawa, H.; Steigerwald, K.; Merl, S.; Nakazawa, G.; John, M. C.; Finn, A. V.; Acampado, E.; Kolodgie, F. D.; Gold, H. K.; Virmani, R. Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1960-1966.
239. Sakai, T.; Kohno, H.; Ishihara, T.; Higaki, M.; Saito, S.; Matsushima, M.; Mizushima, Y.; Kitahara, K: Treatment of experimental autoimmune uveoretinitis with poly[lactic acid]nanoparticles encapsulating betamethasone phosphate. Exp. Eye Res., 2006, 82, 657-663.
240. Adibkia, K.; Omidi, Y.; Siahi, M. R.; Javadzadeh, A. R.; Barzegar- Jalali, M.; Barar, J.; Maleki, N.; Mohammadi, G.; Nokhodchi, A: Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J. Ocul. Pharmacol. Ther., 2007, 23, 421-432.
241. Chvatal, S. A.; Kim, Y. T.; Bratt-Leal, A. M.; Lee, H.; Bellamkonda, R. V. Spatial distribution and acute anti-inflammatory effects of Methylprednisolone after sustained local delivery to the contused spinal cord. Biomaterials, 2008, 29, 1967-1975.
242. Zimmermann, G. R.; Avery, W.; Finelli, A. L.; Farwell, M.; Fraser, C. C.; Borisy, A. A. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res. Ther., 2009, 11, 12-26.
243. Lamprecht, A.; Ubrich, N.; Yamamoto, H.; Schafer, U.; Takeuchi, H.; Maincent, P.; Kawashima, Y.; Lehr, C. M. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther., 2001, 299, 775-781.
244. Lamprecht, A.; Yamamoto, H.; Takeuchi, H.; Kawashima, Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J. Pharmacol. Exp. Ther., 2005, 315, 196-202.
245. Pellequer, Y.; Meissner, Y.; Ubrich, N.; Lamprecht, A. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther., 2007, 321, 726-733.
246. Moulari, B.; Pertuit, D.; Pellequer, Y.; Lamprecht, A. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials, 2008, 29, 4554-4560.
247. Spina, D. PDE4 inhibitors: current status. Br. J. Pharmacol., 2008, 155, 308-315.
248. Flechner, S. M. Reviewing the evidence for de novo immunosuppression with sirolimus. Transplant. Proc., 2008, 40, S25-8.
249. Packard, R. R.; Lichtman, A. H.; Libby, P. Innate and adaptive immunity in atherosclerosis. Semin. Immunopathol., 2009, 31, 5-22.
250. Soehnlein, O.; Weber, C. Myeloid cells in atherosclerosis: initiators and decision shapers. Semin. Immunopathol., 2009, 31, 35-47.
251. Markovsky, E.; Koroukhov, N.; Golomb, G: Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. Nanomed., 2007, 2, 545-553.
252. Cyrus, T.; Zhang, H.; Allen, J. S.; Williams, T. A.; Hu, G.; Caruthers, S. D.; Wickline, S. A.; Lanza, G. M. Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 820-826.
253. Yeh, S.; Faia, L. J.; Nussenblatt, R. B: Advances in the diagnosis and immunotherapy for ocular inflammatory disease Semin. Immunopathol., 2008, 30, 145-164.
254. Bu, H. Z.; Gukasyan, H. J.; Goulet, L.; Lou, X. J.; Xiang, C.; Koudriakova, T. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr. Drug Metab., 2007, 8, 91-107.
255. Sahoo, S. K.; Dilnawaz, F.; Krishnakumar, S. Nanotechnology in ocular drug delivery. Drug Discov. Today, 2008, 13, 144-151.
256. Nagarwal, R. C.; Kant, S.; Singh, P. N.; Maiti, P.; Pandit, J. K. Polymeric nanoparticulate system: a potential approach for ocular drug delivery J. Control. Release, 2009, 136, 2-13.
257. Paolicelli, P.; de la Fuente, M.; Sanchez, A.; Seijo, B.; Alonso, M. J. Chitosan nanoparticles for drug delivery to the eye. Expert Opin. Drug Deliv., 2009, 6, 239-253.
258. Vega, E.; Egea, M. A.; Valls, O.; Espina, M.; Garcia, M. L.: Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J. Pharm. Sci., 2006, 95, 2393-2405.
259. de Kozak, Y.; Andrieux, K.; Villarroya, H.; Klein, C.; Thillaye- Goldenberg, B.; Naud, M. C.; Garcia, E.; Couvreur, P: Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol., 2004, 34, 3702-3712.
260. Kim, S. T.; Jang, D. J.; Kim, J. H.; Park, J. Y.; Lim, J. S.; Lee, S. Y.; Lee, K. M.; Lim, S. J.; Kim, C. K. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. Pharmazie, 2009, 64, 510-514.
261. Schafer-Korting, M.; Mehnert, W.; Korting, H. C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev., 2007, 59, 427-443.
262. Leader, B.; Baca, Q.J.; Golan, D.E. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov., 2008, 7, 21-39.
263. Ratsimandresy, R. A.; Rappaport, J.; Zagury, J. F. Anti-cytokine therapeutics: history and update. Curr. Pharm. Des., 2009, 15, 1998-2025.
264. Mosser, D. M.; Zhang, X. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev., 2008, 226, 205-218.
265. Nakase, H.; Okazaki, K.; Tabata, Y.; Ozeki, M.; Watanabe, N.; Ohana, M.; Uose, S.; Uchida, K.; Nishi, T.; Mastuura, M.; Tamaki, H.; Itoh, T.; Kawanami, C.; Chiba, T. New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J. Pharmacol. Exp. Ther., 2002, 301, 59-65.
266. Nakase, H.; Okazaki, K.; Tabata, Y.; Chiba, T. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. J. Gastroenterol., 2003, 38(Suppl 15), 59-62.
267. Bhavsar, M. D.; Amiji, M. M. Oral IL-10 gene delivery in a microsphere- based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther., 2008, 15, 1200-1209.
268. Fearon, W. F.; Fearon, D. T. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation, 2008, 117, 2577-2579.
269. Zhang, X.; Yu, C.; Xushi; Zhang, C.; Tang, T.; Dai, K. Direct chitosan-mediated gene delivery to the rabbit knee joints in vitro and in vivo. Biochem. Biophys. Res. Commun., 2006, 341, 202-208.
270. Fernandes, J. C.; Wang, H.; Jreyssaty, C.; Benderdour, M.; Lavigne, P.; Qiu, X.; Winnik, F. M.; Zhang, X.; Dai, K.; Shi, Q. Boneprotective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. Mol. Ther., 2008, 16, 1243-1251.
271. Timmons, L.; Fire, A. Specific interference by ingested dsRNA. Nature, 1998, 395, 854.
272. Montgomery, M. K.; Xu, S.; Fire, A. RNA as a target of doublestranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA, 1998, 95, 15502-15507. (Pubitemid 29018728)
273. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature, 1998, 391, 806-811. (Pubitemid 28099681)
274. Voinnet, O. Origin, biogenesis, and activity of plant microRNAs. Cell, 2009, 136, 669-687.
275. Carthew, R.W.; Sontheimer, E. J. Origins and Mechanisms of miRNAs and siRNAs. Cell, 2009, 136, 642-655.
276. Okamura, K.; Chung, W.J.; Lai, E.C. The long and short of inverted repeat genes in animals: microRNAs, mirtrons and hairpin RNAs. Cell Cycle, 2008, 7, 2840-2845.
277. Kim, V. N.; Han, J.; Siomi, M. C. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol., 2009, 10, 126-139.
278. Moazed, D. Small RNAs in transcriptional gene silencing and genome defence. Nature, 2009, 457, 413-420.
279. Jinek, M.; Doudna, J. A. A three-dimensional view of the molecular machinery of RNA interference. Nature, 2009, 457, 405-412.
280. Siomi, H.; Siomi, M. C. On the road to reading the RNAinterference code. Nature, 2009, 457, 396-404.
281. Ghildiyal, M. Small silencing RNAs: an expanding universe. Zamore, P. D. Nat. Rev. Genet., 2009, 10, 94-108.
282. Castanotto, D.; Rossi, J.J. The promises and pitfalls of RNAinterference- based therapeutics. Nature, 2009, 457, 426-433.
283. Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov., 2009, 8, 129-138.
284. White, P. J. Barriers to successful delivery of short interfering RNA after systemic administration. Clin. Exp. Pharmacol. Physiol., 2008, 35, 1371-1376.
285. Akhtar, S.; Benter, I. F. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 2007, 117, 3623-3632.
286. de Fougerolles, A. R. Delivery vehicles for small interfering RNA in vivo. Hum. Gene Ther., 2008, 19, 125-132.
287. Juliano, R.; Alam, M. R.; Dixit, V.; Kang, H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res., 2008, 36, 4158-4171.
288. Yu, B.; Zhao, X.; Lee, L. J.; Lee, R. J. Targeted delivery systems for oligonucleotide therapeutics. AAPS J., 2009, 11, 195-203.
289. Sorensen, D. R.; Leirdal, M.; Sioud, M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol., 2003, 327, 761-766. (Pubitemid 36315917)
290. Khoury, M.; Louis-Plence, P.; Escriou, V.; Noel, D.; Largeau, C.; Cantos, C.; Scherman, D.; Jorgensen, C.; Apparailly, F. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum., 2006, 54, 1867-1877.
291. Khoury, M.; Escriou, V.; Courties, G.; Galy, A.; Yao, R.; Largeau, C.; Scherman, D.; Jorgensen, C.; Apparailly, F. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum., 2008, 58, 2356-2367.
292. Howard, K. A.; Rahbek, U. L.; Liu, X.; Damgaard, C. K.; Glud, S. Z.; Andersen, M. O.; Hovgaard, M. B.; Schmitz, A.; Nyengaard, J. R.; Besenbacher, F.; Kjems, J. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther., 2006, 14, 476-484.
293. Sioud, M.; Sorensen, D. R. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun., 2003, 312, 1220-1225. (Pubitemid 37490947)
294. Ikehara, Y.; Niwa, T.; Biao, L.; Ikehara, S. K.; Ohashi, N.; Kobayashi, T.; Shimizu, Y.; Kojima, N.; Nakanishi, H. A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res., 2006, 66, 8740-8748.
295. Amarzguioui, M.; Lundberg, P.; Cantin, E.; Hagstrom, J.; Behlke, M. A.; Rossi, J. J. Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat. Protoc., 2006, 1, 508-517.
296. Howard, K. A. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Adv. Drug Deliv. Rev., 2009, 61, 710-720.
297. Kuruba, R.; Wilson, A.; Gao, X.; Li, S. Targeted delivery of nucleic- acid-based therapeutics to the pulmonary circulation. AAPS J., 2009, 11, 23-30.
298. Ma, Z.; Zhang, J.; Alber, S.; Dileo, J.; Negishi, Y.; Stolz, D.; Watkins, S.; Huang, L.; Pitt, B.; Li, S. Lipid-mediated delivery of oligonucleotide to pulmonary endothelium. Am. J. Respir. Cell Mol. Biol., 2002, 27, 151-159.
299. Wilson, A.; Zhou, W.; Champion, H. C.; Alber, S.; Tang, Z. L.; Kennel, S.; Watkins, S.; Huang, L.; Pitt, B.; Li, S. Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Mol. Ther., 2005, 12, 510-518.
300. Wang, X.; Xu, W.; Mohapatra, S.; Kong, X.; Li, X.; Lockey, R. F.; Mohapatra, S. S. Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor. Genet. Vaccines Ther., 2008, 6, 7-16.
301. Howard, K. A.; Paludan, S. R.; Behlke, M. A.; Besenbacher, F.; Deleuran, B.; Kjems, J. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 2009, 17, 162-168.
302. Kong, X.; Zhang, W.; Lockey, R. F.; Auais, A.; Piedimonte, G.; Mohapatra, S. S. Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSVNS1 gene. Genet. Vaccines Ther., 2007, 5, 4-12.
303. Zhang, W.; Yang, H.; Kong, X.; Mohapatra, S.; San Juan-Vergara, H.; Hellermann, G.; Behera, S.; Singam, R.; Lockey, R. F.; Mohapatra, S. S. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med., 2005, 11, 56-62.
304. Roman, M.; Calhoun, W. J.; Hinton, K. L.; Avendano, L. F.; Simon, V.; Escobar, A. M.; Gaggero, A.; Diaz, P. V. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am. J. Respir. Crit. Care Med., 1997, 156, 190-195.
305. Matsuse, H.; Behera, A. K.; Kumar, M.; Rabb, H.; Lockey, R. F.; Mohapatra, S. S. Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness. J. Immunol., 2000, 164, 6583-6592.
306. Eckmann, L. Animal models of inflammatory bowel disease: lessons from enteric infections. Ann. N. Y. Acad. Sci., 2006, 1072, 28-38.
307. Polese, L.; Angriman, I.; Scarpa, M.; Norberto, L.; Sturniolo, G. C.; Cecchetto, A.; Ruffolo, C.; D'Amico, D. F. Role of CD40 and B7 costimulators in inflammatory bowel diseases. Acta Biomed., 2003, 74(Suppl 2), 65-70.
308. Gao, D.; Wagner, A.H.; Fankhaenel, S.; Stojanovic, T.; Schweyer, S.; Panzner, S.; Hecker, M. CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut, 2005, 54, 70-77.
309. Zhang, Y.; Cristofaro, P.; Silbermann, R.; Pusch, O.; Boden, D.; Konkin, T.; Hovanesian, V.; Monfils, P. R.; Resnick, M.; Moss, S. F.; Ramratnam, B. Engineering mucosal RNA interference in vivo. Mol. Ther., 2006, 14, 336-342.
310. Peer, D.; Park, E. J.; Morishita, Y.; Carman, C. V.; Shimaoka, M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science, 2008, 319, 627-630.
311. Kakuta, H. Necessity is the mother of invention: an ingenious method for leukocyte-targeted delivery of siRNA in stabilized nanoparticles demonstrates a role of cyclin D1 in inflammation. Chem. Med. Chem., 2008, 3, 1024-1025.
312. Hanai, K.; Kurokawa, T.; Minakuchi, Y.; Maeda, M.; Nagahara, S.; Miyata, T.; Ochiya, T.; Sano, A. Potential of atelocollagenmediated systemic antisense therapeutics for inflammatory disease.' Hum. Gene Ther., 2004, 15, 263-272.
313. Hanai, K.; Takeshita, F.; Honma, K.; Nagahara, S.; Maeda, M.; Minakuchi, Y.; Sano, A.; Ochiya, T. Atelocollagen-mediated systemic DDS for nucleic acid medicines. Ann. N. Y. Acad. Sci., 2006, 1082, 9-17.